Lilly's Triple Agonist, Retatrutide, Successful in Two Additional Phase 3 Obesity Trials, Delivering Significant Improvements in Weight and A1C

Дата публикации: 23-07-2026 21:07:44

INDIANAPOLIS, July 23, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase 3 trials...

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Boehringer Ingelheim Strengthens Obesity Pipeline as Potential First-in-Class Triple Receptor Agonist BI 3034701 Enters Phase II Development	0	13.34	16-07-2026
2	Triple-action drug retatrutide delivers major weight loss for people with diabetes, Phase III trial finds	0	10.14	13-10-2026
3	Eli Lilly alza le stime 2026, boom di Mounjaro e Zepbound	0	12.54	05-08-2026
4	Novo Nordisk porta Eli Lilly in tribunale: si accende la sfida sui farmaci anti-obesità	0	10.48	22-07-2026
5	Novo Nordisk Provides Update on the ZEUS Phase 3 Trial of Ziltivekimab in People with ASCVD, CKD and Inflammation	0	12.26	31-07-2026
6	'Godzilla' weight-loss shot that's more powerful than Ozempic set to be offered to some patients ahead of FDA approval: Find out if you're eligible	0	9.55	04-08-2026
7	Eli Lilly's Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity	7	8	31-07-2025
8	Qual será o próximo grande sucesso no combate à obesidade?	0	5.19	24-04-2026
9	Lilly's Olomorasib Receives U.S. FDA's Breakthrough Therapy Designation for the Treatment of Previously Treated KRAS G12C-Mutant Advanced Pancreatic Cancer	0	9.33	03-08-2026
10	下一个减肥药“爆款”是什么？	0	10	01-05-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 13.62. Источник: www.drugs.com.